Advertisement

The Significance of the Cerebral Dopamine Metabolism in the Pathogenesis and Treatment of Psychotic Disorders

  • H. M. van Praag

Abstract

For many years, well into the Sixties, research into the biological determinants of schizophrenic psychoses has suffered from a dearth of more or less well-founded and testable working hypotheses. Without much system, efforts were made to find abnormal metabolites in a wide variety of body fluids. Strange people, strange substances: not a very powerful research strategy. It has recently dawned, however, that neuroleptics could serve as the pacemaker of biological psychosis research (Matthysse 1973; Snyder, 1974; van Praag 1975), much as the antidepressants are the pacemaker of biological depression research (Van Praag 1976a). I shall briefly discuss the arguments which have led to this conclusion.

Keywords

Psychotic Disorder Fusaric Acid Serum Prolactin Level Neuroleptic Medication Schizophrenic Psychos 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aeden, N.E., Butcher, S.G., Corrodi, H., Fuxe, K., Ungerstedt, U.: Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. J. Pharmacol. 11: 303–314 1970.Google Scholar
  2. Atsmon, A., Blum, I., Maoz, B., Steiner, M., Zeigelman, G., Wijsenbeek, H.: The short-term effects of adrenergic blocking agents in a small group of psychotic patients: preliminary clinical observations. Psychiatr. Neurol. Neurochir. 74: 251–258, 1971.Google Scholar
  3. Atsmon, A., Blum, I., Steiner, M., Latz, A., Wijsenbeek, H.: Further studies with propranolol in psychotic patients. Psychopharma-cologia 27: 249–254, 1972.CrossRefGoogle Scholar
  4. Barbeau, A.: Dopamine and mental function. In: L-DOPA and behavior (ed) S. Malitz, Raven Press, New York, 1972a.Google Scholar
  5. Barbeau, A.: Role of dopamine in the nervous system. Monographs in Human Genetics. 6: 114–130, 1972b.PubMedGoogle Scholar
  6. Bowers, M.B. Jr.: Acute psychosis induced by psychomimetic drug abuse. II. Neurochemical findings. Arch. Gen. Psychiatry. 27: 440–442, 1972.PubMedCrossRefGoogle Scholar
  7. Bowers, M.B. Jr.: Clinical measurements of central dopamine and 5-hydroxytryptamine metabolism: reliability and interpretation of cerebrospinal fluid acid monoamine metabolite measures. Neuropharmacology 11: 101–111, 1972.PubMedCrossRefGoogle Scholar
  8. Bowers, M.B., Jr.: 5-Hydroxyindoleacetic acid (5-HIAA) and homo-vanillic acid (HVA) following probenecid in acute psychotic patients treated with phenothiazines. Psychopharmacologia 28: 309–318, 1973.PubMedCrossRefGoogle Scholar
  9. Bowers, M.B., Jr.: Central dopamine turnover in schizophrenic syndromes. Arch. Gen. Psychiatry. 31: 50–54, 1974.PubMedCrossRefGoogle Scholar
  10. Carlsson, A., Persson, T., Roos, B-E., WäLinder, J.: Potentiation of phenothiazines by α-methyl-tyrosine in treatment of chronic schizophrenia. J. Neural. Transm. 33: 83–90, 1972.PubMedCrossRefGoogle Scholar
  11. Carlsson, A., Roos, B-E., Walinder, J., Skott, A.: Further studies on the mechanism of antipsychotic action: potentiation by α-methyl-tyrosine of thioridazine effects in chronic schizophrenia. J. Neural. Transm. 34: 125–132, 1973.PubMedCrossRefGoogle Scholar
  12. Chase, T.N.: Drug-induced extrapyramidal disorders. In: Neurotransmitters (ed) I.J. Kopin, Williams and Wilkins, Baltimore, 448–471, 1972.Google Scholar
  13. Goodwin, F.K., Post, R.M., Dunner, D.L. and Gordon, E.K.: Cerebrospinal fluid amine metabolism in affective illness: the probenecid technique. Amer. J. Psychiatry 130: 73–79 1973.Google Scholar
  14. Hassler, R., Bak, I.J., Kim, J.S.: Unterschiedliche Entleerung der Speicherorte für Noradrenalin, Dopamin und Serotonin als Wirkungsprinzip des Oxypertins. Nervenartz 41: 105–118, 1970.Google Scholar
  15. Horn, A.S., Post, M.L. and Kennard, O.: Dopamine receptor blockade and the neuroleptics, a crystallographic study. J. Pharm. Pharmacol. 27: 553–563, 1975.PubMedCrossRefGoogle Scholar
  16. Horn, A.S. and Snyder, S.H.: Chlorpromazine and dopamine. Conformational similarities that correlate with the antischizophrenic activity of phenothiazine drugs. Proc. Nat. Ac. Sc. 68: 2325–2328, 1971.CrossRefGoogle Scholar
  17. Hornykiewicz, O: Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 18: 925–964, 1966.PubMedGoogle Scholar
  18. Iversen, L.L.: Dopamine receptors in the brain. Science 188: 1084–1089, 1975.PubMedCrossRefGoogle Scholar
  19. Kirstein, A., Bowers, M,: CSF amine metabolites, clinical symptoms and body movement in psychiatric patients. Biol. Psychiatry, 1976.Google Scholar
  20. Korf, J., Praag, H.M. van: Amine metabolism in human brain: further evaluation of the probenecid test. Brain Res. 35: 221–230, 1971.PubMedCrossRefGoogle Scholar
  21. Korf, J., Praag, H.M. Van, Sebens, J.B.: Effect of intravenously administered probenecid in humans on the levels of 5-hydroxy-indoleacetic acid, homovanillic acid and 3-methoxy-4-hydroxy-phenyl-glycol in cerebrospinal fluid. Biochem. Pharmacol. 20: 659–668, 1971.PubMedCrossRefGoogle Scholar
  22. Korf, J., Schutte, H.H., Venema, K.: A semi-automated fluorometric determination of 5-hydroxyindoles in the nanogram range. Anal. Biochem. 53: 146–153, 1973.PubMedCrossRefGoogle Scholar
  23. Matthysse, I.: Antipsychotic drug actions: a clue to the neuropathology of schizophrenia? Feder. Proc. 32: 200–205, 1973.Google Scholar
  24. Meltzer, H., Sachar, E.J., Frantz, A.G.: Serum prolactin levels in unmedicated schizophrenic patients. Arch. Gen. Psychiatry. 31: 564–569, 1974.PubMedCrossRefGoogle Scholar
  25. Meltzer, H., Sachar, E.J., Frantz, A.G.: Dopamine antagonism by thioridazine in schizophrenia. Biol. Psychiatry. 10: 53–57, 197, 1975.PubMedGoogle Scholar
  26. Munkvad, I., Fog, R., Randrup, A.: Amphetamine psychosis: A useful model of schizophrenia? In: On the origin of schizophrenic psychoses. (ed) H.M van Praag, De Erven Bohn B.V. Amsterdam, 1975.Google Scholar
  27. Nyb ä ck, H., Sedvall, G.: Further studies on the accumulation and disappearance of catecholamines formed from-14C in mouse brain. Effect of some phenothiazine analogues. Eur. J. Pharmacol. 10: 193–205, 1970.PubMedCrossRefGoogle Scholar
  28. O’keefe, R., Sharman, D.F., Vogt, M.: Effect of drugs used in psychoses on cerebral dopamine metabolism. Br. J. Pharmacol. 38: 287–304, 1970.Google Scholar
  29. Post, R.M., Fink, E., Carpenter, W.T., Goodwin, F.K.: Cerebrospinal fluid amine metabolites in acute schizophrenia. Arch. Gen. Psychiatry 32: 1063–1069, 1975.PubMedCrossRefGoogle Scholar
  30. Praag, H.M. van.: The possible significance of cerebral dopamine for neurology and psychiatry. Psychiatr. Neurol. Neurochir. 70: 361–379, 1967.PubMedGoogle Scholar
  31. Praag, H.M. van.: The position of biological psychiatry among the psychiatric disciplines. Compr. Psychiatry. 12: 1–7, 1971.PubMedCrossRefGoogle Scholar
  32. Praag, H.M. van., Korf, J., Schut, T.: Cerebral monoamines and depression. An investigation into their correlation with the aid of the probenecid technique. Arch. Gen. Psychiatry. 28: 827–831, 1973.PubMedCrossRefGoogle Scholar
  33. Praag, H.M. van, Korf, J., Lakke, J.P.W.F., Schut, T.: Dopamine metabolism in depressions, psychoses and parkinson’s disease:the problem of the specificity of biological variables in behavior disorders. Psychol. Med. 5: 138–146, 1975a.PubMedCrossRefGoogle Scholar
  34. Praag, H.M. van., Dols, L.C.W., Schut, T.: Biochemical versus psychopathological action profile of neuroleptics: A comparative study of chlorpromazine and oxypertine in acute psychotic disorders. Compr. Psychiatry. 16: 255–263, 1975b.PubMedCrossRefGoogle Scholar
  35. Praag, H.M. van.: Neuroleptics as a guideline to biological research in psychotic disorders. Compr. Psychiatry. 16: 7–22, 1975.PubMedCrossRefGoogle Scholar
  36. Praag. H.M. van., Korf, J.: Neuroleptics, catecholamines and psychotic disorders. A study of their interrelation. Amer. J. Psychiatry 132: 593–597, 1975a.Google Scholar
  37. Praag, H.M. van., Korf, J.: The importance in the pathogenesis of psychosis and the actions of antipsychotic (neuroleptic) drugs. Proceedings of the Sixth International Congress of Pharmacology, Helsinki, 1975b (in press).Google Scholar
  38. Praag, H.M. van.: Monoamine metabolism in affective disorders. In: Current developments in psychopharmacology (eds) W.B. Essman and L. Valzelli, Vol. 4, Spectrum Publications, New York, 1976b.Google Scholar
  39. Praag, H.M. van.: Monoamine metabolism in schizophrenic psychosis. In: Current Developments in psychopharmacology (eds) W.B. Essman and L. Valzelli, Vol. 4, Spectrum Publication, New York, 1976b.Google Scholar
  40. Praag, H.M. van., Korf, J.: Importance of the dopamine metabolism for the clinical effects and side effects of neuroleptics. Amer. J. Psychiatry. 1976.Google Scholar
  41. Praag, H..M. van.: About the impossible concept of schizophrenia. Compr. Psychiatry (in press), 1976c.Google Scholar
  42. Praag, H.M. van., Korf, J., Dols, L.C.W.: A comparative investigation of the biochemical and clinical effects of clozapine and perphenazine in acute psychotic patients (in press) 1976.Google Scholar
  43. Randrup, A., Munkvad, I.: Biochemical anatomical and psychological investigations of stereotyped behavior induced by amphetamines.In: Amphetamines and related compounds. (eds) E. Costa and S. Garattini, Raven Press, New York, 695–713, 1970.Google Scholar
  44. Randrup, A., Munkvad, I.: Evidence indicating an association between schizophrenia and dopaminergic hyperactivity in the brain. Orthomolecul. Psychiatry. 1: 2–27, 1972.Google Scholar
  45. Sack, R.L. and Goodwin, F.K.: Inhibition of dopamine-β-hydroxylase in manic patients. Arch. Gen. Psychiat. 31: 649–654, 1974.PubMedCrossRefGoogle Scholar
  46. Seeman, P., Lee, T.: Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188: 1217–1219, 1975.PubMedCrossRefGoogle Scholar
  47. Sjöström, R., Roos, B-E.: 5-Hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid in manic-depressive psychosis. Europ. J. Pharmacol. 4: 170–176, 1972.CrossRefGoogle Scholar
  48. Snyder, S.H., Taylor, K.M., Coyle, J.R., Meyerhoff, J.L.: The role of brain dopamine in behavioural regulation and the actions of psychotropic drugs. Amer. J. Psychiatry. 127: 199–207, 1970.Google Scholar
  49. Snyder, S.H.: Amphetamine psychosis: a “model” schizophrenia mediated by catecholamines. Amer. J. Psychiatry. 130: 6l–66, 1973.Google Scholar
  50. Snyder, S.H., Banerjee, S.P., Yamamura, H.I., Greenberg, D.: Drugs, neurotransmitters and schizophrenia. Science 184: 1243–1253, 1974.PubMedCrossRefGoogle Scholar
  51. Steiner, M., Latz, A., Blum, I., Atsmon, A., Wijsenbeek, H.: Propranolol ersus chlorpromazine in the treatment of psychoses associated with childbearing. Psychiatr. Neurol. Neurochir. 76: 421–426, 1973.PubMedGoogle Scholar
  52. Svensson, T.H., Waldeck, B.: On the role of brain catecholamines in motor activity: experiments with inhibitors of synthesis and monoamine oxidase. Psychopharmacologia 18: 357–365, 1970.PubMedCrossRefGoogle Scholar
  53. Westerink, B.H.C., Korf, J.: Influence of drugs on striatal and limbic homovanillic acid concentration in the rat brain. Europ. J. Pharmacol. 33: 31–40, 1975a.CrossRefGoogle Scholar
  54. Westerink, B.H.C., Korf, J.: Determination of nanogram amounts of homovanillic acid in the central nervous system with a rapid semi-automated fluorometric method. Biochem. Med. 12: 106–114, 1975b.PubMedCrossRefGoogle Scholar
  55. Wiesel, F.A, Sedvall, G.: Effect of antipsychotic drugs on homovanillic acid levels in striatum and olfactory tubercle of the rat. Europ. J. Pharmacol. 30: 36U–367, 1975.CrossRefGoogle Scholar
  56. Wilson, R.G., Hamilton, J.R., Boyd, W.D., Forrest, A.P.M., Cole, E.N.Google Scholar
  57. Boyns, A.R., Griffiths, K.: The effect of long-term pheno-thiazine therapy on plasma prolactin. Brit. J. Psychiatry. 127: 71–74, 1975.CrossRefGoogle Scholar
  58. Yorkston, N.J., Zaki, S.A., Malik, M.K.U., Morrisoh, B.C., Harvard, C.W.H.: Propranolol in the control of schizophrenic symptoms. Brit. Med. J. 4: 633–635, 1974.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1977

Authors and Affiliations

  • H. M. van Praag
    • 1
  1. 1.Department of Biological PsychiatryState University GröningenThe Netherlands

Personalised recommendations